©FabienMalotParis-based drugmaker Sanofi closed 2025 with strong growth and upbeat guidance, but its latest results also reveal sharp pipeline cuts that underline a tougher phase for R&D choices.
Lonza GroupCDMOs are currently setting the agenda across the industry. Alongside peers such as Vetter, Lonza has now delivered a clear statement of intent: strong results, sharper focus and an even more determined commitment to its core business. But the stronger investment strategy internationally frightens Switzerland – at least some analysts.
Vetter PharmaWith an initial investment of around €480 million, Ravensburg-based Vetter Pharma has now fleshed out its plans to expand operations in Saarlouis, Saarland. The former automotive site is to be redeveloped by 2031 and is expected to employ up to 2,000 people in contract development and manufacturing.
International Journal of Molecular Sciences, doi: 10.3390/ijms17040561 JO - sPositive signals from a partnership with Takeda are allowing Heidelberg Pharma to push the setback from a milestone payment not received as planned from Telix somewhat into the background. Nevertheless, the company has been strongly shaken and is now hoping for calmer waters in order to drive its clinical development forward with greater focus.
It’s a busy day for U.K.-based Tenpoint Therapeutics, which has secured U.S. Food and Drug Administration (FDA) approval for YUVEZZI, a combination eye drop for the treatment of presbyopia, while raising $235 million to support its commercial rollout at the same time.
RocheRoche made a clear statement in 2025. The Basel-based group increased sales by 7% at constant exchange rates to CHF 61.5bn (€67bn) and lifted core operating profit by as much as 13%. For many observers, this represents far more than just a solid set of annual results.
French biotech company Sensorion announced today a €60 million (about $72 million) reserved offering including a €20 million strategic investment from Sanofi. The remaining €40 million subscribed by existing shareholders Redmile Group, Artal (advised by Invus), and Sofinnova Partners, alongside new investors including Cormorant Asset Management, Coastlands Capital, and Sphera Healthcare, which are leading US Healthcare Specialists funds.
Boehringer IngelheimBoehringer Ingelheim is continuing its international shopping tour for innovative drug candidates – and once again ends up in China. The German pharmaceutical group has entered into a licensing and development partnership with Shanghai-based Simcere Pharmaceutical Group to advance a novel bispecific antibody for the treatment of inflammatory bowel disease (IBD).
Olga Yastremska, New Africa, freepikDresden-based experts in sequence-precise gene repair, Seamless Therapeutics, have secured a heavyweight partner. The company has entered into a global research collaboration with the world’s largest pharmaceutical company by market cap, Eli Lilly, to apply its technology platform of specific recombinases to the development of gene therapies for hearing loss. For Seamless, the collaboration could generate total funding of up to USD 1.1 billion if milestones are successfully achieved.
Few biotech pivots are as jarring as Genenta’s latest move.
The Milan-based company, which went public in late 2021 on the promise of a novel cell-based gene therapy platform, is now effectively abandoning the single-asset biotech playbook. Instead, it wants to become something far closer to a holding company for defense, aerospace, cybersecurity, and national-security assets, starting with a manufacturer of tactical rifles.